Krystal Biotech, Inc.
$308.89-$6.93 (-2.2%)
Last close · Data as of Nov 20, 2026
- Market cap
- $9.1B
- P/E
- 44.3x
- EV / EBITDA
- 51.2x
- Revenue
- $389.1M
- Net margin
- 52.6%
- ROCE
- 13.1%
Price chart
Technical chartScreen technicals →+51.2% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -5.1%
- 3M
- -8.3%
- 6M
- +2.3%
- 1Y
- +51.2%
- 5Y
- Hidden
- This period includes a one-day price step on 29 Nov 2021 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
52-week range
Day change -$6.93 (-2.2%) from $316 to $309 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in KRYS, bought on each weekday since 2021.
News & filings
What Krystal Biotech filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthOperating margin of 41.5% against a peer median of 5.8%.
Concerns (1)
- The P/E of 44.3 is 103% above the peer median of 21.8.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Read moreShow less
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
- Sector
- Healthcare
- Shares outstanding
- 28.9M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $9.1B
- P/E
- 44.3x
- P/B
- 7.4x
- EV / EBITDA
- 51.2x
- EV / Sales
- 22.1x
- P/S
- 23.3x
- 52-week high
- $378.15
- 52-week low
- $204.23
Profitability
- Operating margin
- 41.5%
- Net margin
- 52.6%
- EBITDA margin
- 43.1%
- ROE
- 16.8%
- ROCE
- 13.1%
- ROA
- 15.4%
- Asset turnover
- 0.29
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $389.1M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 33.9%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 129.7%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $188.9M
Solvency
- Current ratio
- 9.95
- Debt / Equity
- 0.01
- Debt / Assets
- 0.01
- CFO / Net profit
- 0.98
- Cash / Market cap
- 5.5%
Where the revenue went
Of every $100 of FY2025 revenue, $53 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $23.1M |
| Revenue | Gross profit | $366.1M |
| Gross profit | Research and development | $58.0M |
| Gross profit | Selling, general and administrative | $146.7M |
| Gross profit | Other operating expenses | $10.0k |
| Gross profit | Operating income | $161.3M |
| Operating income | Pretax income | $161.3M |
| Interest and other income | Pretax income | $28.2M |
| Pretax income | Net income | $189.5M |
| Tax benefit and other | Net income | $15.4M |
Revenue and net profit
Revenue grew 33.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $0.00 | -$140.0M |
| FY2023 | $50.7M | $10.9M |
| FY2024 | $290.5M | $89.2M |
| FY2025 | $389.1M | $204.8M |
Cash flows
FY2025: $200.9M from operations, $188.9M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$100.6M | -$153.5M |
| FY2023 | -$88.8M | -$100.6M |
| FY2024 | $123.4M | $119.2M |
| FY2025 | $200.9M | $188.9M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $389.1M+33.9%1Y
- EBITDA
- $167.8M+52.6%1Y
- Net profit
- $204.8M+129.7%1Y
- Cash from operations
- $200.9M+62.7%1Y
- Free cash flow
- $188.9M+58.5%1Y
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $389.1M | $167.8M | $204.8M | $188.9M | 16.8% | +33.9% | +129.7% |
Monthly returns
Month-by-month returns of KRYS across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $1.3B |
| Current assets | $1.0B |
| Non-current assets | $309.2M |
| Liabilities | $114.2M |
| Current liabilities | $102.9M |
| Non-current liabilities | $11.3M |
| Equity | $1.2B |
| Paid-in capital | $1.2B |
| Retained earnings | $24.2M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; KRYS highlighted.
P/E against peers
KRYS trades at 44.3x earnings against a peer median of 21.8x (a 103% premium).
Not shown (no positive earnings and no EV / Sales): Baxter International Inc., Charles River Laboratories International, Inc., Glaukos Corporation.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Krystal Biotech, Inc.KRYSthis companyP/E ↑ premium | $9.1B | 44.3x | 7.4x | 16.8% | 51.2x |
| Molina Healthcare, Inc.MOH | $10.0B | 21.3x | 2.5x | 11.6% | — |
| Baxter International Inc.BAX | $10.0B | -10.4x | 1.6x | -15.6% | 23.2x |
| Charles River Laboratories International, Inc.CRL | $8.9B | — | 2.8x | -4.6% | 27.5x |
| Henry Schein, Inc.HSIC | $8.7B | 21.8x | 2.7x | 12.3% | 12.4x |
| Bio-Techne CorporationTECH | $8.3B | 113.5x | 4.3x | 3.8% | 39.7x |
| Corcept Therapeutics IncorporatedCORT | $8.0B | 80.7x | 12.4x | 15.4% | 66.1x |
| Alkermes plcALKS | $7.2B | 29.9x | 4.0x | 13.3% | 20.9x |
| Glaukos CorporationGKOS | $7.1B | -38.1x | 10.9x | -28.6% | -49.0x |
| Peer median | — | 21.8x | 3.4x | 7.7% | 23.2x |
Year-to-date ROI
KRYS since 1 January, against earlier years.
Historical volatility
KRYS's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2023 | -191.6% |
| FY2024 | 35.5% |
| FY2025 | 41.4% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $389.1M |
| Cost of revenueCost Of Revenue | $23.1M |
| Gross profitGross Profit | $366.1M |
| Operating expensesOperating Expense | $204.8M |
| Research and developmentResearch And Development | $58.0M |
| Selling, general and administrativeSelling General And Administration | $146.7M |
| Total expensesTotal Expenses | $227.8M |
| Operating incomeOperating Income | $161.3M |
| Interest and other | |
| Pretax incomePretax Income | $189.5M |
| TaxTax Provision | -$15.4M |
| Net incomeNet Income | $204.8M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $1.3B |
| Current assetsCurrent Assets | $1.0B |
| Non-current assetsTotal Non Current Assets | $309.2M |
| LiabilitiesTotal Liabilities Net Minority Interest | $114.2M |
| Current liabilitiesCurrent Liabilities | $102.9M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $11.3M |
| EquityTotal Equity Gross Minority Interest | $1.2B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $200.9M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $200.9M |
| Net income, continuing operationsNet Income From Continuing Operations | $204.8M |
| Depreciation and amortisationDepreciation And Amortization | $6.5M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $6.5M |
| Depreciation | $6.5M |
| Amortization of securitiesAmortization Of Securities | -$500.0k |
| Stock-based compensationStock Based Compensation | $54.5M |
| Deferred taxDeferred Tax | -$22.8M |
| Deferred income taxDeferred Income Tax | -$22.8M |
| Operating gains and lossesOperating Gains Losses | -$6.0M |
| Gain loss on investment securitiesGain Loss On Investment Securities | -$6.0M |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | — |
| Unrealized gain loss on investment securitiesUnrealized Gain Loss On Investment Securities | — |
| Change in working capitalChange In Working Capital | -$36.4M |
| Other non-cash itemsOther Non Cash Items | $680.0k |
| Investing cash flowInvesting Cash Flow | -$58.4M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$58.4M |
| Capital expenditureCapital Expenditure | -$11.9M |
| Purchase of PP&EPurchase Of PPE | -$11.9M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$11.9M |
| Purchase of investmentsPurchase Of Investment | -$422.5M |
| Sale of investmentsSale Of Investment | $375.6M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$46.9M |
| Other investing changesNet Other Investing Changes | $440.0k |
| Financing cash flowFinancing Cash Flow | $8.7M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $8.7M |
| Shares issuedIssuance Of Capital Stock | $0.00 |
| Common stock issuedCommon Stock Issuance | $0.00 |
| Net common stock issuedNet Common Stock Issuance | $0.00 |
| Stock options exercisedProceeds From Stock Option Exercised | $22.7M |
| Other financing chargesNet Other Financing Charges | -$14.0M |
| Change in cashChanges In Cash | $151.2M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 29.0% |
| Cash at the start of the yearBeginning Cash Position | $344.9M |
| Cash at the end of the yearEnd Cash Position | $496.3M |
| Free cash flowFree Cash Flow | $188.9M |
| Supplemental |
Learn while you research
Academy chapters picked for Krystal Biotech, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Valuation Multiples ExplainedThis stock trades at a P/E of 44.3, learn when high multiples are justified.6 min read
- 03 Growth Investing34% revenue growth is in the top tier, learn how to value growth.7 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read